MarketPulse
F

$FULC

3 articles found
3 positive
0 negative
0 neutral
GlobeNewswire Inc.GlobeNewswire Inc.··Not Specified

Fulcrum Therapeutics Advances Sickle Cell Program With Positive Data, Eyes 2029 Runway

Fulcrum Therapeutics reports positive pociredir data in sickle cell disease, plans registration trial in H2 2026, maintains $333.3M cash runway through 2029.
FULCclinical trialFDA
GlobeNewswire Inc.GlobeNewswire Inc.··Na

MedicAlert, SCDAA, and Fulcrum Partner to Speed Emergency Care for Sickle Cell Patients

MedicAlert Foundation, SCDAA, and Fulcrum Therapeutics launch three-year partnership to improve emergency department access to sickle cell patients' critical care information via smart medical ID cards.
FULCsickle cell diseasehealthcare partnership
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Fulcrum's Pociredir Shows Strong Hemoglobin Gains in Sickle Cell Phase 1b Trial

Fulcrum's pociredir shows strong fetal hemoglobin gains in sickle cell Phase 1b trial, with 58% of patients reaching therapeutic levels and reduced pain crises.
FULCrare diseaseclinical trial results